Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications

被引:42
作者
Takei, Hidehiro [1 ]
Rouah, Emilie [2 ]
Ishida, Yusuke [3 ]
机构
[1] Asahikawa Med Univ, Dept Diagnost Pathol, Asahikawa, Hokkaido 0788510, Japan
[2] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA
[3] Hokkaido Univ, Grad Sch Med, Dept Clin Pathol, Sapporo, Hokkaido, Japan
关键词
Brain metastasis; Immunohistochemistry; Differential diagnosis; Unique histologic patterns; Molecular alterations; CENTRAL-NERVOUS-SYSTEM; CELL LUNG-CANCER; CEREBROSPINAL-FLUID CSF; HIPPEL-LINDAU-DISEASE; OF-THE-LITERATURE; BREAST-CANCER; MALIGNANT-MELANOMA; SUBDURAL-HEMATOMA; SOLID TUMORS; LEPTOMENINGEAL METASTASES;
D O I
10.1007/s10014-015-0235-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastases are the most common brain tumors especially in adults. Although they are generally considered a single disease entity which is universally fatal in patients with advanced cancer, brain metastases are remarkably heterogeneous both clinically and pathologically. As members of the multidisciplinary clinical team for the diagnosis and management of metastatic brain tumors, pathologists must be familiar not only with clinicopathologic features of brain metastases but also with any characteristic and clinically significant molecular findings. We discuss here the epidemiology, general gross and microscopic features of brain metastases with emphasis on how to differentiate them from primary brain tumors using immunohistochemistry (e.g., for identification of the primary site and differential diagnosis), and unique pathologic patterns of brain metastases (namely, dural metastasis, leptomeningeal carcinomatosis, miliary metastasis, "intravascular carcinomatosis", and tumor-to-tumor metastasis) with their clinical and radiological characteristics. We specifically address metastatic breast and non-small cell lung cancers which are the two most commonly encountered in daily practice, with emphasis on the molecular alterations related to therapy and their clinicopathologic significance.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 79 条
[71]  
TURNER DM, 1982, NEUROSURGERY, V11, P678, DOI 10.1227/00006123-198211000-00011
[72]   Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline [J].
Van Poznak, Catherine ;
Somerfield, Mark R. ;
Bast, Robert C. ;
Cristofanilli, Massimo ;
Goetz, Matthew P. ;
Gonzalez-Angulo, Ana M. ;
Hicks, David G. ;
Hill, Elizabeth G. ;
Liu, Minetta C. ;
Lucas, Wanda ;
Mayer, Ingrid A. ;
Mennel, Robert G. ;
Symmans, William F. ;
Hayes, Daniel F. ;
Harris, Lyndsay N. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) :2695-U174
[73]  
WASSERSTROM WR, 1982, CANCER-AM CANCER SOC, V49, P759, DOI 10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO
[74]  
2-7
[75]   Breast cancer metastasis to the central nervous system [J].
Weil, RJ ;
Palmieri, DC ;
Bronder, JL ;
Stark, AM ;
Steeg, PS .
AMERICAN JOURNAL OF PATHOLOGY, 2005, 167 (04) :913-920
[76]  
YAP HY, 1978, CANCER-AM CANCER SOC, V42, P283, DOI 10.1002/1097-0142(197807)42:1<283::AID-CNCR2820420142>3.0.CO
[77]  
2-#
[78]  
ZHANG ET, 1990, J ANAT, V170, P111
[79]   Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer [J].
Zhang, Jingze ;
Yu, Jinming ;
Sun, Xindong ;
Meng, Xue .
CANCER LETTERS, 2014, 351 (01) :6-12